Launched in September by Dr Abasi Ene-Obong, previously founder and CEO of the now-defunct Nigerian genomics startup 54gene, alongside Dr Jumi Popoola and Estelle Dogbo, Syndicate Bio is leveraging collaborations with governments, pharmaceutical companies, academia and other key industry stakeholders to deepen local precision medicine impact while generating invaluable datasets that improve global health outcomes and accelerates drug discovery and development. The company, which in November announced a strategic partnership with the National Institute for Cancer Research and Treatment (NICRAT) to initiate the Cancer Genome Nigeria project. The implementation of the new genomic profiling and liquid biopsy technology will further existing work from SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center (MSK), and Syndicate Bio to advance health equity on a global scale.
SOURCE: DISRUPT AFRICA
The First Lab in Africa to Make Comprehensive Genomic Profiling and Liquid Biopsy Accessible
